PLx Pharma (PLXP) Releases Earnings Results, Meets Expectations
PLx Pharma (NASDAQ:PLXP) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.39) EPS for the quarter, meeting analysts’ consensus estimates of ($0.39), MarketWatch Earnings reports. PLx Pharma had a negative return on equity of 169.28% and a negative net margin of 12.57%. The company had revenue of $0.22 million during the quarter.
Shares of NASDAQ:PLXP traded down $0.04 on Friday, reaching $3.85. 1,360 shares of the company traded hands, compared to its average volume of 4,015. PLx Pharma has a fifty-two week low of $3.05 and a fifty-two week high of $7.60. The company has a market capitalization of $32.32 million, a PE ratio of -1.97 and a beta of 1.68. The company has a debt-to-equity ratio of 0.93, a quick ratio of 9.15 and a current ratio of 9.15.
Separately, ValuEngine upgraded PLx Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd.
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.